Skip to main content
Erschienen in: Neurotoxicity Research 4/2014

01.05.2014 | Original Article

A Critical Evaluation of Behavioral Rodent Models of Motor Impairment Used for Screening of Antiparkinsonian Activity: The Case of Adenosine A2A Receptor Antagonists

verfasst von: Annalisa Pinna, Micaela Morelli

Erschienen in: Neurotoxicity Research | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Animal models of motor dysfunction constitute the basis for the screening of new drugs with potential efficacy in diseases characterized by motor impairment, such as Parkinson’s Disease (PD). Taking adenosine A2A receptor antagonists as an example of a new class of drugs for PD, the review will examine the most utilized rodent models of motor impairment and the results reported in the literature with this class of drugs. The results obtained so far in rodent models of PD suggested that A2A receptor antagonists might have symptomatic therapeutic efficacy in PD. They may ameliorate initiation of movement, gait and muscle rigidity, sensorimotor integration deficits, and tremor. Moreover, A2A receptor antagonists when administered with a low sub-threshold dose of l-DOPA potentiated its efficacy. However, the clinical trials so far performed have evaluated their efficacy in the “ON/OFF” of PD patients with motor complications, showing a limited efficacy of this class of drug. Therefore, on one hand, animal models of PD might have a limited validity; on the other hand, clinical trials should explore the efficacy of A2A receptor antagonists on a broader range of parkinsonian conditions.
Literatur
Zurück zum Zitat Bara-Jimenez W, Sherzai A, Dimitrova T, Favit A, Bibbiani F, Gillespie M et al (2003) Adenosine A(2A) receptor antagonist treatment of Parkinson’s disease. Neurology 61:293–296PubMedCrossRef Bara-Jimenez W, Sherzai A, Dimitrova T, Favit A, Bibbiani F, Gillespie M et al (2003) Adenosine A(2A) receptor antagonist treatment of Parkinson’s disease. Neurology 61:293–296PubMedCrossRef
Zurück zum Zitat Betz AJ, Vontell R, Valenta J, Worden L, Sink KS, Font L, Correa M, Sager TN, Salamone JD (2009) Effects of the adenosine A2A antagonist KW 6002 (istradefylline) on pimozide-induced oral tremor and striatal c-Fos expression: comparisons with the muscarinic antagonist tropicamide. Neuroscience 163:97–108PubMedCrossRef Betz AJ, Vontell R, Valenta J, Worden L, Sink KS, Font L, Correa M, Sager TN, Salamone JD (2009) Effects of the adenosine A2A antagonist KW 6002 (istradefylline) on pimozide-induced oral tremor and striatal c-Fos expression: comparisons with the muscarinic antagonist tropicamide. Neuroscience 163:97–108PubMedCrossRef
Zurück zum Zitat Bibbiani F, Oh JD, Petzer JP, Castagnoli N Jr, Chen JF, Schwarzschild MA et al (2003) A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson’s disease. Exp Neurol 184:285–294PubMedCrossRef Bibbiani F, Oh JD, Petzer JP, Castagnoli N Jr, Chen JF, Schwarzschild MA et al (2003) A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson’s disease. Exp Neurol 184:285–294PubMedCrossRef
Zurück zum Zitat Bové J, Marin C, Bonastre M, Tolosa E (2002) Adenosine A2A antagonism reverses levodopa-induced motor alterations in hemiparkinsonian rats. Synapse 15:251–257CrossRef Bové J, Marin C, Bonastre M, Tolosa E (2002) Adenosine A2A antagonism reverses levodopa-induced motor alterations in hemiparkinsonian rats. Synapse 15:251–257CrossRef
Zurück zum Zitat Bové J, Serrats J, Mengod G, Cortés R, Aguilar E, Marin C (2006) Reversion of levodopa-induced motor fluctuations by the A2A antagonist CSC is associated with an increase in striatal preprodynorphin mRNA expression in 6-OHDA-lesioned rats. Synapse 59:435–444PubMedCrossRef Bové J, Serrats J, Mengod G, Cortés R, Aguilar E, Marin C (2006) Reversion of levodopa-induced motor fluctuations by the A2A antagonist CSC is associated with an increase in striatal preprodynorphin mRNA expression in 6-OHDA-lesioned rats. Synapse 59:435–444PubMedCrossRef
Zurück zum Zitat Carlsson A, Lindqvist M, Magnusson T (1957) 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180:1200PubMedCrossRef Carlsson A, Lindqvist M, Magnusson T (1957) 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180:1200PubMedCrossRef
Zurück zum Zitat Carta AR, Frau L, Pinna A, Pontis S, Simola N, Schintu N, Morelli M (2008) Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat. Synapse 62:524–533PubMedCrossRef Carta AR, Frau L, Pinna A, Pontis S, Simola N, Schintu N, Morelli M (2008) Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat. Synapse 62:524–533PubMedCrossRef
Zurück zum Zitat Chang JW, Wachtel SR, Young D, Kang UJ (1999) Biochemical and anatomical characterization of foreforelimb adjusting steps in rat models of Parkinson’s disease: studies on medial forebrain bundle and striatal lesions. Neuroscience 88:617–628PubMedCrossRef Chang JW, Wachtel SR, Young D, Kang UJ (1999) Biochemical and anatomical characterization of foreforelimb adjusting steps in rat models of Parkinson’s disease: studies on medial forebrain bundle and striatal lesions. Neuroscience 88:617–628PubMedCrossRef
Zurück zum Zitat Collins LE, Galtieri DJ, Brennum LT, Sager TN, Hockemeyer J, Müller CE et al (2010) Oral tremor induced by the muscarinic agonist pilocarpine is suppressed by the adenosine A2A antagonists MSX-3 and SCH58261, but not the adenosine A1 antagonist DPCPX. Pharmacol Biochem Behav 94:561–569PubMedCrossRef Collins LE, Galtieri DJ, Brennum LT, Sager TN, Hockemeyer J, Müller CE et al (2010) Oral tremor induced by the muscarinic agonist pilocarpine is suppressed by the adenosine A2A antagonists MSX-3 and SCH58261, but not the adenosine A1 antagonist DPCPX. Pharmacol Biochem Behav 94:561–569PubMedCrossRef
Zurück zum Zitat Collins LE, Sager TN, Sams AG, Pennarola A, Port RG, Shahriari M, Salamone JD (2012) The novel adenosine A2A antagonist Lu AA47070 reverses the motor and motivational effects produced by dopamine D2 receptor blockade. Pharmacol Biochem Behav 100:498–505PubMedCrossRef Collins LE, Sager TN, Sams AG, Pennarola A, Port RG, Shahriari M, Salamone JD (2012) The novel adenosine A2A antagonist Lu AA47070 reverses the motor and motivational effects produced by dopamine D2 receptor blockade. Pharmacol Biochem Behav 100:498–505PubMedCrossRef
Zurück zum Zitat Collins-Praino LE, Paul NE, Rychalsky KL, Hinman JR, Chrobak JJ, Senatus PB, Salamone JD (2011) Pharmacological and physiological characterization of the tremulous jaw movement model of parkinsonian tremor: potential insights into the pathophysiology of tremor. Front Syst Neurosci 5:49PubMedCentralPubMedCrossRef Collins-Praino LE, Paul NE, Rychalsky KL, Hinman JR, Chrobak JJ, Senatus PB, Salamone JD (2011) Pharmacological and physiological characterization of the tremulous jaw movement model of parkinsonian tremor: potential insights into the pathophysiology of tremor. Front Syst Neurosci 5:49PubMedCentralPubMedCrossRef
Zurück zum Zitat Correa M, Wisniecki A, Betz A, Dobson DR, O’Neill MF, O’Neill MJ et al (2004) The adenosine A2A antagonist KF17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism. Behav Brain Res 148:47–54PubMedCrossRef Correa M, Wisniecki A, Betz A, Dobson DR, O’Neill MF, O’Neill MJ et al (2004) The adenosine A2A antagonist KF17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism. Behav Brain Res 148:47–54PubMedCrossRef
Zurück zum Zitat Cousins MS, Carriero DL, Salamone JD (1997) Tremulous jaw movements induced by the acetylcholinesterase inhibitor tacrine: effects of antiparkinsonian drugs. Eur J Pharmacol 322:137–145PubMedCrossRef Cousins MS, Carriero DL, Salamone JD (1997) Tremulous jaw movements induced by the acetylcholinesterase inhibitor tacrine: effects of antiparkinsonian drugs. Eur J Pharmacol 322:137–145PubMedCrossRef
Zurück zum Zitat Drabczyńska A, Zygmunt M, Sapa J, Filipek B, Müller CE, Kieć-Kononowicz K (2011) Antiparkinsonian effects of novel adenosine A(2A) receptor antagonists. Arch Pharm (Weinheim) 344:20–27CrossRef Drabczyńska A, Zygmunt M, Sapa J, Filipek B, Müller CE, Kieć-Kononowicz K (2011) Antiparkinsonian effects of novel adenosine A(2A) receptor antagonists. Arch Pharm (Weinheim) 344:20–27CrossRef
Zurück zum Zitat Duty S, Jenner P (2011) Animal models of Parkinson’s disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol 164:1357–1391PubMedCentralPubMedCrossRef Duty S, Jenner P (2011) Animal models of Parkinson’s disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol 164:1357–1391PubMedCentralPubMedCrossRef
Zurück zum Zitat Duvoisin RC, Marsden CD (1974) Reversal of reserpine-induced bradykinesia by alpha-methyldopa—new light on its modus operandi. Brain Res 71:178–182PubMedCrossRef Duvoisin RC, Marsden CD (1974) Reversal of reserpine-induced bradykinesia by alpha-methyldopa—new light on its modus operandi. Brain Res 71:178–182PubMedCrossRef
Zurück zum Zitat Ekstrand MI, Terzioglu M, Galter D, Zhu S, Hofstetter C, Lindqvist E, Thams S et al (2007) Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc Natl Acad Sci USA 104:1325–1330PubMedCentralPubMedCrossRef Ekstrand MI, Terzioglu M, Galter D, Zhu S, Hofstetter C, Lindqvist E, Thams S et al (2007) Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc Natl Acad Sci USA 104:1325–1330PubMedCentralPubMedCrossRef
Zurück zum Zitat Elazar Z, Ganchrow D, Paz M, Rabinowitz R, Paz Z, Korczyn AD (1990) Dopaminergic drugs influence the intensity of catalepsy induced by microinjections of carbachol into the reticular formation. Neurosci Lett 119:245–248PubMedCrossRef Elazar Z, Ganchrow D, Paz M, Rabinowitz R, Paz Z, Korczyn AD (1990) Dopaminergic drugs influence the intensity of catalepsy induced by microinjections of carbachol into the reticular formation. Neurosci Lett 119:245–248PubMedCrossRef
Zurück zum Zitat Fenu S, Pinna A, Ongini E, Morelli M (1997) Adenosine A2A receptor antagonism potentiates l-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. Eur J Pharmacol 321:143–147PubMedCrossRef Fenu S, Pinna A, Ongini E, Morelli M (1997) Adenosine A2A receptor antagonism potentiates l-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. Eur J Pharmacol 321:143–147PubMedCrossRef
Zurück zum Zitat Fredduzzi S, Moratalla R, Monopoli A, Cuellar B, Xu K, Ongini E et al (2002) Persistent behavioral sensitization to chronic l-DOPA requires A2A adenosine receptors. J Neurosci 22:1054–1062PubMed Fredduzzi S, Moratalla R, Monopoli A, Cuellar B, Xu K, Ongini E et al (2002) Persistent behavioral sensitization to chronic l-DOPA requires A2A adenosine receptors. J Neurosci 22:1054–1062PubMed
Zurück zum Zitat Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE (1999) Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 51:83–133PubMed Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE (1999) Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 51:83–133PubMed
Zurück zum Zitat Gerlach M, Riederer P (1996) Animal models of Parkinson’s disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 103:987–1041PubMedCrossRef Gerlach M, Riederer P (1996) Animal models of Parkinson’s disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 103:987–1041PubMedCrossRef
Zurück zum Zitat Gillespie RJ, Bamford SJ, Botting R, Comer M, Denny S, Gaur S et al (2009) Antagonists of the human A2A adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines. J Med Chem 52:33–47PubMedCrossRef Gillespie RJ, Bamford SJ, Botting R, Comer M, Denny S, Gaur S et al (2009) Antagonists of the human A2A adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines. J Med Chem 52:33–47PubMedCrossRef
Zurück zum Zitat Halldner L, Lozza G, Lindström K, Fredholm BB (2000) Lack of tolerance to motor stimulant effects of a selective adenosine A(2A) receptor antagonist. Eur J Pharmacol 406:345–354PubMedCrossRef Halldner L, Lozza G, Lindström K, Fredholm BB (2000) Lack of tolerance to motor stimulant effects of a selective adenosine A(2A) receptor antagonist. Eur J Pharmacol 406:345–354PubMedCrossRef
Zurück zum Zitat Hauser RA, Hubble JP, Truong DD (2003) Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 61:297–303PubMedCrossRef Hauser RA, Hubble JP, Truong DD (2003) Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 61:297–303PubMedCrossRef
Zurück zum Zitat Hauser RA, Shulman LM, Trugman JM, Roberts J, Mori A, Ballerini R et al (2008) Study of istradefylline in patients with Parkinson’s disease on levodopa with motor fluctuations. Mov Disord 23:2177–2185PubMedCrossRef Hauser RA, Shulman LM, Trugman JM, Roberts J, Mori A, Ballerini R et al (2008) Study of istradefylline in patients with Parkinson’s disease on levodopa with motor fluctuations. Mov Disord 23:2177–2185PubMedCrossRef
Zurück zum Zitat Hauser RA, Cantillon M, Pourcher E, Micheli F, Mok V, Onofrj M et al (2011) Preladenant in patients with Parkinson’s disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol 10:221–229PubMedCrossRef Hauser RA, Cantillon M, Pourcher E, Micheli F, Mok V, Onofrj M et al (2011) Preladenant in patients with Parkinson’s disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol 10:221–229PubMedCrossRef
Zurück zum Zitat Henry B, Crossman AR, Brotchie JM (1998) Characterization of enhanced behavioral responses to l-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson’s disease. Exp Neurol 151:334–342PubMedCrossRef Henry B, Crossman AR, Brotchie JM (1998) Characterization of enhanced behavioral responses to l-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson’s disease. Exp Neurol 151:334–342PubMedCrossRef
Zurück zum Zitat Hodgson RA, Bertorelli R, Varty GB, Lachowicz JE, Forlani A, Fredduzzi S et al (2009) Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 in rodent models of movement disorders and depression. J Pharmacol Exp Ther 33:294–303CrossRef Hodgson RA, Bertorelli R, Varty GB, Lachowicz JE, Forlani A, Fredduzzi S et al (2009) Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 in rodent models of movement disorders and depression. J Pharmacol Exp Ther 33:294–303CrossRef
Zurück zum Zitat Horst WD, Pool WR, Spiegel HE (1973) Correlation between brain dopamine levels and l-dopa activity in anti-Parkinson tests. Eur J Pharmacol 21:337–342PubMedCrossRef Horst WD, Pool WR, Spiegel HE (1973) Correlation between brain dopamine levels and l-dopa activity in anti-Parkinson tests. Eur J Pharmacol 21:337–342PubMedCrossRef
Zurück zum Zitat Ishiwari K, Betz A, Weber S, Felsted J, Salamone JD (2005) Validation of the tremulous jaw movement model for assessment of the motor effects of typical and atypical antipychotics: effects of pimozide (Orap) in rats. Pharmacol Biochem Behav 80:351–362PubMedCrossRef Ishiwari K, Betz A, Weber S, Felsted J, Salamone JD (2005) Validation of the tremulous jaw movement model for assessment of the motor effects of typical and atypical antipychotics: effects of pimozide (Orap) in rats. Pharmacol Biochem Behav 80:351–362PubMedCrossRef
Zurück zum Zitat Jin S, Fredholm BB (1997) Adenosine A2A receptor stimulation increases release of acetylcholine from rat hippocampus but not striatum, and does not affect catecholamine release. Naunyn Schmiedebergs Arch Pharmacol 355:48–56PubMedCrossRef Jin S, Fredholm BB (1997) Adenosine A2A receptor stimulation increases release of acetylcholine from rat hippocampus but not striatum, and does not affect catecholamine release. Naunyn Schmiedebergs Arch Pharmacol 355:48–56PubMedCrossRef
Zurück zum Zitat Kanda T, Shiozaki S, Shimada J, Suzuki F, Nakamura J (1994) KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity. Eur J Pharmacol 256:263–268PubMedCrossRef Kanda T, Shiozaki S, Shimada J, Suzuki F, Nakamura J (1994) KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity. Eur J Pharmacol 256:263–268PubMedCrossRef
Zurück zum Zitat Kobayashi T, Araki T, Itoyama Y, Takeshita M, Ohta T, Oshima Y (1997) Effects of l-dopa and bromocriptine on haloperidol-induced motor deficits in mice. Life Sci 61:2529–2538PubMedCrossRef Kobayashi T, Araki T, Itoyama Y, Takeshita M, Ohta T, Oshima Y (1997) Effects of l-dopa and bromocriptine on haloperidol-induced motor deficits in mice. Life Sci 61:2529–2538PubMedCrossRef
Zurück zum Zitat Koga K, Kurokawa M, Ochi M, Nakamura J, Kuwana Y (2000) Adenosine A(2A) receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats. Eur J Pharmacol 408:249–255PubMedCrossRef Koga K, Kurokawa M, Ochi M, Nakamura J, Kuwana Y (2000) Adenosine A(2A) receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats. Eur J Pharmacol 408:249–255PubMedCrossRef
Zurück zum Zitat Kurokawa M, Kirk IP, Kirkpatrick KA, Kase H, Richardson PJ (1994) Inhibition by KF17837 of adenosine A2A receptor-mediated modulation of striatal GABA and ACh release. Br J Pharmacol 113:43–48PubMedCentralPubMedCrossRef Kurokawa M, Kirk IP, Kirkpatrick KA, Kase H, Richardson PJ (1994) Inhibition by KF17837 of adenosine A2A receptor-mediated modulation of striatal GABA and ACh release. Br J Pharmacol 113:43–48PubMedCentralPubMedCrossRef
Zurück zum Zitat Lorenc-Koci E, Wolfarth S, Ossowska K (1996) Haloperidol-increased muscle tone in rats as a model of parkinsonian rigidity. Exp Brain Res 109:268–276PubMedCrossRef Lorenc-Koci E, Wolfarth S, Ossowska K (1996) Haloperidol-increased muscle tone in rats as a model of parkinsonian rigidity. Exp Brain Res 109:268–276PubMedCrossRef
Zurück zum Zitat Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA (2002) Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson’s disease. Eur J Neurosci 15:120–132PubMedCrossRef Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA (2002) Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson’s disease. Eur J Neurosci 15:120–132PubMedCrossRef
Zurück zum Zitat Lundblad M, Vaudano E, Cenci MA (2003) Cellular and behavioural effects of the adenosine A2A receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia. J Neurochem 84:1398–1410PubMedCrossRef Lundblad M, Vaudano E, Cenci MA (2003) Cellular and behavioural effects of the adenosine A2A receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia. J Neurochem 84:1398–1410PubMedCrossRef
Zurück zum Zitat Mandhane SN, Chopde CT, Ghosh AK (1997) Adenosine A2 receptors modulate haloperidol-induced catalepsy in rats. Eur J Pharmacol 328:135–141PubMedCrossRef Mandhane SN, Chopde CT, Ghosh AK (1997) Adenosine A2 receptors modulate haloperidol-induced catalepsy in rats. Eur J Pharmacol 328:135–141PubMedCrossRef
Zurück zum Zitat Marcellino D, Lindqvist E, Schneider M, Müller CE, Fuxe K, Olson L, Galter D (2010) Chronic A2A antagonist treatment alleviates parkinsonian locomotor deficiency in MitoPark mice. Neurobiol Dis 40:460–466PubMedCrossRef Marcellino D, Lindqvist E, Schneider M, Müller CE, Fuxe K, Olson L, Galter D (2010) Chronic A2A antagonist treatment alleviates parkinsonian locomotor deficiency in MitoPark mice. Neurobiol Dis 40:460–466PubMedCrossRef
Zurück zum Zitat Marin C, Aguilar E, Bonastre M, Tolosa E, Obeso JA (2005) Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats. Exp Neurol 192:184–193PubMedCrossRef Marin C, Aguilar E, Bonastre M, Tolosa E, Obeso JA (2005) Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats. Exp Neurol 192:184–193PubMedCrossRef
Zurück zum Zitat Mayorga AJ, Carriero DL, Cousins MS, Gianutsos G, Salamone JD (1997) Tremulous jaw movements produced by acute tacrine administration: possible relation to parkinsonian side effects. Pharmacol Biochem Behav 56:273–279PubMedCrossRef Mayorga AJ, Carriero DL, Cousins MS, Gianutsos G, Salamone JD (1997) Tremulous jaw movements produced by acute tacrine administration: possible relation to parkinsonian side effects. Pharmacol Biochem Behav 56:273–279PubMedCrossRef
Zurück zum Zitat Meredith GE, Kang UJ (2006) Behavioral models of Parkinson’s disease in rodents: a new look at an old problem. Mov Disord 21:1595–1606PubMedCrossRef Meredith GE, Kang UJ (2006) Behavioral models of Parkinson’s disease in rodents: a new look at an old problem. Mov Disord 21:1595–1606PubMedCrossRef
Zurück zum Zitat Mizuno Y, Hasegawa K, Kondo T, Kuno S, Yamamoto M (2010) Clinical efficacy of istradefylline (KW-6002) in Parkinson’s disease: a randomized, controlled study. Mov Disord 25:1437–1443PubMedCrossRef Mizuno Y, Hasegawa K, Kondo T, Kuno S, Yamamoto M (2010) Clinical efficacy of istradefylline (KW-6002) in Parkinson’s disease: a randomized, controlled study. Mov Disord 25:1437–1443PubMedCrossRef
Zurück zum Zitat Morelli M, Pinna A (2001) Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson’s disease. Neurol Sci 22:71–72PubMedCrossRef Morelli M, Pinna A (2001) Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson’s disease. Neurol Sci 22:71–72PubMedCrossRef
Zurück zum Zitat Neustadt BR, Hao J, Lindo N, Greenlee WJ, Stamford AW, Tulshian D et al (2007) Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines. Bioorg Med Chem Lett 17:1376–1380PubMedCrossRef Neustadt BR, Hao J, Lindo N, Greenlee WJ, Stamford AW, Tulshian D et al (2007) Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines. Bioorg Med Chem Lett 17:1376–1380PubMedCrossRef
Zurück zum Zitat Obeso JA, Rodriguez-Oroz MC, Rodriguez M, Macias R, Alvarez L, Guridi J et al (2000) Pathophysiologic basis of surgery for Parkinson’s disease. Neurology 55:S7–S12PubMedCrossRef Obeso JA, Rodriguez-Oroz MC, Rodriguez M, Macias R, Alvarez L, Guridi J et al (2000) Pathophysiologic basis of surgery for Parkinson’s disease. Neurology 55:S7–S12PubMedCrossRef
Zurück zum Zitat Oh JD, Chase TN (2002) Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson’s disease. Amino Acids 23:133–139PubMedCrossRef Oh JD, Chase TN (2002) Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson’s disease. Amino Acids 23:133–139PubMedCrossRef
Zurück zum Zitat Olanow CW (2004) The scientific basis for the current treatment of Parkinson’s disease. Annual Rev Med 55:41–60CrossRef Olanow CW (2004) The scientific basis for the current treatment of Parkinson’s disease. Annual Rev Med 55:41–60CrossRef
Zurück zum Zitat Olsson M, Nikkhah G, Bentlage C, Bjorklund A (1995) Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci 15:3863–3875PubMed Olsson M, Nikkhah G, Bentlage C, Bjorklund A (1995) Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci 15:3863–3875PubMed
Zurück zum Zitat Papa SM, Engber TM, Kask AM, Chase TN (1994) Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res 662:69–74PubMedCrossRef Papa SM, Engber TM, Kask AM, Chase TN (1994) Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res 662:69–74PubMedCrossRef
Zurück zum Zitat Pinna A, Di Chiara G, Wardas J, Morelli M (1996) Blockade of A2A adenosine receptors positively modulates turning behaviour and c-Fos expression induced by D1 agonists in dopamine-denervated rats. Eur J Neurosci 8:1176–1181PubMedCrossRef Pinna A, Di Chiara G, Wardas J, Morelli M (1996) Blockade of A2A adenosine receptors positively modulates turning behaviour and c-Fos expression induced by D1 agonists in dopamine-denervated rats. Eur J Neurosci 8:1176–1181PubMedCrossRef
Zurück zum Zitat Pinna A, Fenu S, Morelli M (2001) Motor stimulant effects of the adenosine A(2A) receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats. Synapse 39:233–238CrossRef Pinna A, Fenu S, Morelli M (2001) Motor stimulant effects of the adenosine A(2A) receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats. Synapse 39:233–238CrossRef
Zurück zum Zitat Pinna A, Corsi C, Carta AR, Valentini V, Pedata F, Morelli M (2002) Modification of adenosine extracellular levels and adenosine A(2A) receptor mRNA by dopamine denervation. Eur J Pharmacol 446:75–82PubMedCrossRef Pinna A, Corsi C, Carta AR, Valentini V, Pedata F, Morelli M (2002) Modification of adenosine extracellular levels and adenosine A(2A) receptor mRNA by dopamine denervation. Eur J Pharmacol 446:75–82PubMedCrossRef
Zurück zum Zitat Pinna A, Volpini R, Cristalli G, Morelli M (2005) New adenosine A2A receptor antagonists: actions on Parkinson’s disease models. Eur J Pharmacol 512:157–164PubMedCrossRef Pinna A, Volpini R, Cristalli G, Morelli M (2005) New adenosine A2A receptor antagonists: actions on Parkinson’s disease models. Eur J Pharmacol 512:157–164PubMedCrossRef
Zurück zum Zitat Pinna A, Pontis S, Morelli M (2006) Expression of dyskinetic movements and turning behaviour in subchronic l-DOPA 6-hydroxydopamine-treated rats is influenced by the testing environment. Behav Brain Res 171:175–178PubMedCrossRef Pinna A, Pontis S, Morelli M (2006) Expression of dyskinetic movements and turning behaviour in subchronic l-DOPA 6-hydroxydopamine-treated rats is influenced by the testing environment. Behav Brain Res 171:175–178PubMedCrossRef
Zurück zum Zitat Pinna A, Pontis S, Borsini F, Morelli M (2007) Adenosine A(2A) receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson’s disease. Synapse 61:606–614PubMedCrossRef Pinna A, Pontis S, Borsini F, Morelli M (2007) Adenosine A(2A) receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson’s disease. Synapse 61:606–614PubMedCrossRef
Zurück zum Zitat Pinna A, Tronci E, Schintu N, Simola N, Volpini R, Pontis S et al (2010) A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug. Neuropharmacology 58:613–623PubMedCrossRef Pinna A, Tronci E, Schintu N, Simola N, Volpini R, Pontis S et al (2010) A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug. Neuropharmacology 58:613–623PubMedCrossRef
Zurück zum Zitat Pollack AE, Fink JS (1996) Synergistic interaction between an adenosine antagonist and a D1 dopamine agonist on rotational behaviour and striatal c-Fos induction in 6-hydroxydopamine-lesioned rats. Brain Res 743:124–130PubMedCrossRef Pollack AE, Fink JS (1996) Synergistic interaction between an adenosine antagonist and a D1 dopamine agonist on rotational behaviour and striatal c-Fos induction in 6-hydroxydopamine-lesioned rats. Brain Res 743:124–130PubMedCrossRef
Zurück zum Zitat Rose S, Ramsay Croft N, Jenner P (2007) The novel adenosine A2A antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats. Brain Res 1133:110–114PubMedCrossRef Rose S, Ramsay Croft N, Jenner P (2007) The novel adenosine A2A antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats. Brain Res 1133:110–114PubMedCrossRef
Zurück zum Zitat Salamone JD, Mayorga AJ, Trevitt JT, Cousins MS, Conlan A, Nawab A (1998) Tremulous jaw movements in rats: a model of parkinsonian tremor. Prog Neurobiol 56:591–611PubMedCrossRef Salamone JD, Mayorga AJ, Trevitt JT, Cousins MS, Conlan A, Nawab A (1998) Tremulous jaw movements in rats: a model of parkinsonian tremor. Prog Neurobiol 56:591–611PubMedCrossRef
Zurück zum Zitat Salamone JD, Betz AJ, Ishiwari K, Felsted J, Madson L, Mirante B et al (2008) Tremorolytic effects of adenosine A2A antagonists: implications for parkinsonism. Front Biosci 13:3594–3605PubMedCrossRef Salamone JD, Betz AJ, Ishiwari K, Felsted J, Madson L, Mirante B et al (2008) Tremorolytic effects of adenosine A2A antagonists: implications for parkinsonism. Front Biosci 13:3594–3605PubMedCrossRef
Zurück zum Zitat Schallert T, Fleming SM, Leasure JL, Tillerson JL, Bland ST (2000) CNS plasticity and assessment of forelimb sensiromotor outcome in unilateral rat model of stroke, cortical ablation, parkinsonism, and spinal cord injury. Neuropharmacology 39:777–787PubMedCrossRef Schallert T, Fleming SM, Leasure JL, Tillerson JL, Bland ST (2000) CNS plasticity and assessment of forelimb sensiromotor outcome in unilateral rat model of stroke, cortical ablation, parkinsonism, and spinal cord injury. Neuropharmacology 39:777–787PubMedCrossRef
Zurück zum Zitat Schwarting RK, Huston JP (1996) The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol 50:275–331PubMedCrossRef Schwarting RK, Huston JP (1996) The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol 50:275–331PubMedCrossRef
Zurück zum Zitat Shiozaki S, Ichikawa S, Nakamura J, Kitamura S, Yamada K, Kuwana Y (1999) Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology 147:90–95PubMedCrossRef Shiozaki S, Ichikawa S, Nakamura J, Kitamura S, Yamada K, Kuwana Y (1999) Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology 147:90–95PubMedCrossRef
Zurück zum Zitat Shook BC, Rassnick S, Osborne MC, Davis S, Westover L, Boulet J, Hall D, Rupert KC et al (2010) In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson’s disease. J Med Chem 53:8104–8115PubMedCrossRef Shook BC, Rassnick S, Osborne MC, Davis S, Westover L, Boulet J, Hall D, Rupert KC et al (2010) In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson’s disease. J Med Chem 53:8104–8115PubMedCrossRef
Zurück zum Zitat Shook BC, Rassnick S, Wallace N, Crooke J, Ault M, Chakravarty D, Barbay JK, Wang A et al (2012) Design and characterization of optimized adenosine A2/A1 receptor antagonists for the treatment of Parkinson’s disease. J Med Chem 55:1402–1417PubMedCrossRef Shook BC, Rassnick S, Wallace N, Crooke J, Ault M, Chakravarty D, Barbay JK, Wang A et al (2012) Design and characterization of optimized adenosine A2/A1 receptor antagonists for the treatment of Parkinson’s disease. J Med Chem 55:1402–1417PubMedCrossRef
Zurück zum Zitat Simola N, Fenu S, Baraldi PG, Tabrizi MA, Morelli M (2004) Blockade of adenosine A2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions. Exp Neurol 189:182–188PubMedCrossRef Simola N, Fenu S, Baraldi PG, Tabrizi MA, Morelli M (2004) Blockade of adenosine A2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions. Exp Neurol 189:182–188PubMedCrossRef
Zurück zum Zitat Simola N, Fenu S, Baraldi PG, Tabrizi MA, Morelli M (2006) Dopamine and adenosine receptor interaction as basis for the treatment of Parkinson’s disease. J Neurol Sci 248:48–52PubMedCrossRef Simola N, Fenu S, Baraldi PG, Tabrizi MA, Morelli M (2006) Dopamine and adenosine receptor interaction as basis for the treatment of Parkinson’s disease. J Neurol Sci 248:48–52PubMedCrossRef
Zurück zum Zitat Simola N, Morelli M, Carta AR (2007) The 6-hydroxydopamine model of Parkinson’s disease. Neurotox Res 11:151–167PubMedCrossRef Simola N, Morelli M, Carta AR (2007) The 6-hydroxydopamine model of Parkinson’s disease. Neurotox Res 11:151–167PubMedCrossRef
Zurück zum Zitat Stacy M, Silver D, Mendis T, Sutton J, Mori A, Chaikin P et al (2008) A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology 70:2233–2240PubMedCrossRef Stacy M, Silver D, Mendis T, Sutton J, Mori A, Chaikin P et al (2008) A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology 70:2233–2240PubMedCrossRef
Zurück zum Zitat Stasi MA, Borsini F, Varani K, Vincenzi F, Di Cesare MA, Minetti P et al (2006) ST 1535: a preferential A2A adenosine receptor antagonist. Int J Neuropsychopharmacol 9:575–584PubMedCrossRef Stasi MA, Borsini F, Varani K, Vincenzi F, Di Cesare MA, Minetti P et al (2006) ST 1535: a preferential A2A adenosine receptor antagonist. Int J Neuropsychopharmacol 9:575–584PubMedCrossRef
Zurück zum Zitat Tronci E, Simola N, Borsini F, Schintu N, Frau L, Carminati P et al (2007) Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats. Eur J Pharmacol 566:94–102PubMedCrossRef Tronci E, Simola N, Borsini F, Schintu N, Frau L, Carminati P et al (2007) Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats. Eur J Pharmacol 566:94–102PubMedCrossRef
Zurück zum Zitat Ungerstedt U (1968) 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 5:107–110PubMedCrossRef Ungerstedt U (1968) 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 5:107–110PubMedCrossRef
Zurück zum Zitat Vellucci SV, Sirinathsinghji DJ, Richardson PJ (1993) Adenosine A2 receptor regulation of apomorphine-induced turning in rats with unilateral striatal dopamine denervation. Psychopharmacology 111:383–388PubMedCrossRef Vellucci SV, Sirinathsinghji DJ, Richardson PJ (1993) Adenosine A2 receptor regulation of apomorphine-induced turning in rats with unilateral striatal dopamine denervation. Psychopharmacology 111:383–388PubMedCrossRef
Zurück zum Zitat Villanueva-Toledo J, Moo-Puc RE, Góngora-Alfaro JL (2003) Selective A2A, but not A1 adenosine antagonists enhance the anticataleptic action of trihexyphenidyl in rats. Neurosci Lett 346:1–4PubMedCrossRef Villanueva-Toledo J, Moo-Puc RE, Góngora-Alfaro JL (2003) Selective A2A, but not A1 adenosine antagonists enhance the anticataleptic action of trihexyphenidyl in rats. Neurosci Lett 346:1–4PubMedCrossRef
Zurück zum Zitat Wardas J (2003) Synergistic effect of SCH 58261, an adenosine A2A receptor antagonist, and l-DOPA on the reserpine-induced muscle rigidity in rats. Pol J Pharmacol 55:155–164PubMed Wardas J (2003) Synergistic effect of SCH 58261, an adenosine A2A receptor antagonist, and l-DOPA on the reserpine-induced muscle rigidity in rats. Pol J Pharmacol 55:155–164PubMed
Zurück zum Zitat Wardas J, Konieczny J, Lorenc-Koci E (2001) SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats. Synapse 41:160–171PubMedCrossRef Wardas J, Konieczny J, Lorenc-Koci E (2001) SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats. Synapse 41:160–171PubMedCrossRef
Zurück zum Zitat Weiss SM, Benwell K, Cliffe IA, Gillespie RJ, Knight AR, Lerpiniere J, Misra A, Pratt RM, Revell D, Upton R, Dourish CT (2003) Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson’s disease. Neurology 61:S101–S106PubMedCrossRef Weiss SM, Benwell K, Cliffe IA, Gillespie RJ, Knight AR, Lerpiniere J, Misra A, Pratt RM, Revell D, Upton R, Dourish CT (2003) Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson’s disease. Neurology 61:S101–S106PubMedCrossRef
Zurück zum Zitat Xiao D, Bastia E, Xu YH, Benn CL, Cha JH, Peterson TS et al (2006) Forebrain adenosine A2A receptors contribute to l-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice. J Neurosci 26:13548–13555PubMedCrossRef Xiao D, Bastia E, Xu YH, Benn CL, Cha JH, Peterson TS et al (2006) Forebrain adenosine A2A receptors contribute to l-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice. J Neurosci 26:13548–13555PubMedCrossRef
Metadaten
Titel
A Critical Evaluation of Behavioral Rodent Models of Motor Impairment Used for Screening of Antiparkinsonian Activity: The Case of Adenosine A2A Receptor Antagonists
verfasst von
Annalisa Pinna
Micaela Morelli
Publikationsdatum
01.05.2014
Verlag
Springer US
Erschienen in
Neurotoxicity Research / Ausgabe 4/2014
Print ISSN: 1029-8428
Elektronische ISSN: 1476-3524
DOI
https://doi.org/10.1007/s12640-013-9446-8

Weitere Artikel der Ausgabe 4/2014

Neurotoxicity Research 4/2014 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Neurologie

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.